Clinical Trials Sponsored by Noden Pharma

Total 8270 results

Noden Pharma

Completed

52-104 Week Off-therapy Second Extension to Study CSPP100A2365

Hypertension

Turkey, United States, Guatemala, Slovakia, Hungary, Puerto Rico, Poland
Noven Pharmaceuticals, Inc.

Completed

Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia. (HP-3070)

Schizophrenia

United States
Noven Therapeutics
Noven Pharmaceuticals, Inc.

Completed

Efficacy, Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD

Attention Deficit Disorder With Hyperactivity
Noven Therapeutics

Completed

Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women (N30-005)

Postmenopausal Symptoms

United States
Noven Pharmaceuticals, Inc.

Recruiting

Study Will Assess Skin Irritation and Sensitization for HP-1050 Patch

Cumulative Irritation and Sensitization

United States
Noven Pharmaceuticals, Inc.

Completed

A 4-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Knee Osteoarthritis (HP-5000)

Osteoarthritis of the Knee

United States
Noven Therapeutics
Noven Pharmaceuticals, Inc.

Completed

Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD and Previously Participated in MTS Trials

Attention Deficit Disorder With Hyperactivity
Noven Pharmaceuticals, Inc.

Completed

Study to Evaluate Safety & Efficacy of d-Amphetamine Transdermal System vs Placebo in Children & Adolescents With ADHD

Attention Deficit Hyperactivity Disorder

United States
Noven Pharmaceuticals, Inc.

Completed

A 12-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Osteoarthritis Pain of the Knee

Osteoarthritis Pain of the Knee

United States
Noven Pharmaceuticals, Inc.

Completed

Irritation and Sensitization Study of HP-5000 Topical System

Osteoarthritis of the Knee

United States
Noven Therapeutics
Noven Pharmaceuticals, Inc.

Completed

Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy

Attention Deficit Disorder With Hyperactivity

United States
Noven Therapeutics

Completed

Irritation and Sensitization Study of d-Amphetamine Transdermal System (dATS)

Cumulative Irritation and Sensitization

United States
Noven Therapeutics

Completed

Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS) (N30-003)

Postmenopausal Symptoms

United States
Noven Therapeutics

Completed

Classroom Study to Assess Efficacy and Safety of MTS in Pediatric Patients Aged 6-12 With ADHD

Attention Deficit Disorder With Hyperactivity

United States
Noven Therapeutics

Completed

Safety and Efficacy of MTS Versus Concerta in Pediatric Patients (Aged 6-12 Years) With ADHD

Attention Deficit Hyperactivity Disorder
Noven Therapeutics

Completed

Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

ADHD

United States
Noven Therapeutics

Completed

Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

ADHD

United States
Noven Therapeutics

Completed

Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA

Attention Deficit Hyperactivity Disorder

United States
Noven Therapeutics

Completed

24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms

Hot Flashes

United States
Noven Therapeutics

Completed

Eight-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms Associated With Menopause

Hot Flashes

United States
R-Pharm
Covance; Cromos Pharma LLC

Withdrawn

Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).

COVID-19
UCB BIOSCIENCES, Inc.
R-Pharm

Terminated

Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056

Rheumatoid Arthritis

United States, Belgium, United Kingdom
AJU Pharm Co., Ltd.
OM Pharma SA

Recruiting

The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Chronic Prostatitis With Chronic Pelvic Pain Syndrome | Chronic Prostatitis | Chronic Pelvic Pain Syndrome

Korea, Republic of
UCB BIOSCIENCES, Inc.
R-Pharm

Terminated

The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Japan, Korea, Republic of, Taiwan
Yuria-Pharm
Pharmaxi LLC

Completed

Epidemiological Study of the COVID-2019 in Participating Organizations.

Covid19

Ukraine
PT Sydna Farma
PT Pharma Metric Labs

Completed

Bioequivalence Study of Cyproterone Acetate and Ethinyl Estradiol in Healthy Female Volunteers

Drug Use

Indonesia
Monash University
Caring Pharmacy; Bionime Corporation; Tigas Pharma

Active, not recruiting

Prevention and Treatment of Diabetes in Adults

PreDiabetes

Malaysia
UCB Biopharma S.P.R.L.
Pharm Research Associates (UK) Ltd.

Completed

Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures (BASE)

Epilepsy With POS With or Without Secondary Generalization

Denmark, Germany, Hungary, Ireland, Italy, Netherlands, Norway, Spain, United Kingdom
UCB Pharma SA

Completed

Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy

Epilepsy

United States, Belgium, Czechia, France, Germany, Hungary, Ireland, Italy, Mexico, Poland, Spain, United Kingdom
UCB Pharma SA

Completed

Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam

Epilepsy, Partial

Canada, United States
Vifor Pharma, Inc.

Terminated

Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia (EMERALD)

Hyperkalemia

United States, Bulgaria, Canada, Georgia, Germany, Poland, Ukraine
UCB Pharma SA

Completed

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

Epilepsy

Belgium, Finland, France, Germany, Hungary, India, Italy, Netherlands, Poland, Spain, Switzerland, United Kingdom
UCB Pharma SA

Completed

Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy

Generalized Epilepsy
UCB Pharma SA

Completed

Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)

Dermatitis, Atopic
UCB Pharma SA

Completed

A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] (PRECiSE 3)

Crohn's Disease

United States, Australia, Austria, Belarus, Belgium, Bulgaria, Czechia, Denmark, Estonia, Germany, Hungary, Israel, Italy, New Zealand, Norway, Poland, Russian Federation, Serbia, Singapore, Slovenia, South Africa, Spain, Ukraine, Canada and more
NicOx
Theradis pharma; Iris Pharma

Withdrawn

Efficacy and Safety of Iota-Carrageenan Eye Drops (NCX-4240) (Goldeneye)

Adenoviral Conjunctivitis

Spain
UCB Pharma GmbH

Completed

Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy (VICTOS)

Focal Epilepsy With and Without Secondary Generalization

Germany, Austria
UCB Pharma SA

Completed

Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults

Unverricht-Lundborg Disease

France, Italy, Sweden, Finland, Netherlands, Tunisia, Réunion
UCB Pharma SA

Completed

Bioavailability/Bioequivalence Study Between Lacosamide Tablet and Solution for Infusion in Healthy Japanese Subjects

Healthy Volunteers

United Kingdom
UCB Pharma SA

Terminated

Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's Disease (REFRESH-PD)

Advanced Idiopathic Parkinson's Disease

United Kingdom
Astellas Pharma Inc
Advanz Pharma

Completed

Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter

Atrial Fibrillation | Atrial Flutter

United States, Argentina, Canada, Chile, Denmark, Mexico, Sweden
PT. Pyridam Farma Tbk
PT Pharma Metric Labs

Completed

Bioequivalence Study of Metformin Hydrochloride 500 mg Film-Coated Tablets in Indonesia Healthy Subject

Drug Use

Indonesia
Laboratories Leon Farma, S.A.
Chemo France

Completed

Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles

Contraception

United States
Vifor Pharma, Inc.

Recruiting

Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age

Hyperkalemia

United States, Israel
Vifor Pharma, Inc.

Terminated

FDDA Utilization Study (FDDAU)

Fatigue

Switzerland
UCB Pharma SA

Completed

Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors (NexT)

Rheumatoid Arthritis

Germany
UCB Pharma SA

Completed

Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.

Epilepsy, Tonic-clonic

Poland, Sweden, Hungary, Czechia
UCB Pharma SA

Completed

A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease (PRECiSE 4)

Crohn's Disease

United States, Australia, Austria, Belarus, Belgium, Bulgaria, Canada, Czechia, Denmark, Estonia, Germany, Hungary, Israel, Italy, New Zealand, Norway, Poland, Russian Federation, Serbia, Singapore, Slovenia, South Africa, Spain, Ukraine
UCB Pharma SA

Completed

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis (C-early)

Rheumatoid Arthritis

Germany, United States, Argentina, Australia, Austria, Belgium, Canada, Colombia, Czechia, France, Hungary, Ireland, Italy, Mexico, Monaco, Netherlands, Poland, Romania, Spain, Sweden, Switzerland, United Kingdom
UCB Pharma SA

Completed

Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy

Epilepsy

United States, France, Germany, Spain

3

Subscribe